Juliane Winkelmann

List of Publications by Year
in descending order

109	19,637	31976 53	26613 107
papers	citations	h-index	g-index

113	113	113	28198
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Hostâ€“microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature, 2012, 491, 119-124.	27.8	4,038
2	Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature, 2011, 476, 214-219.	27.8	2,400
3	Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nature Genetics, 2013, 45, 1353-1360.	21.4	1,213
4	Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nature Genetics, 2012, 44, 1341-1348.	21.4	848
5	A Mutation in VPS35, Encoding a Subunit of the Retromer Complex, Causes Late-Onset Parkinson Disease. American Journal of Human Genetics, 2011, 89, 168-175.	6.2	757
6	Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions. Nature Genetics, 2007, 39, 1000-1006.	21.4	633
7	Mutant Adenosine Deaminase 2 in a Polyarteritis Nodosa Vasculopathy. New England Journal of Medicine, 2014, 370, 921-931.	27.0	566
8	Mutations in the gene encoding É›-sarcoglycan cause myoclonusâ€“dystonia syndrome. Nature Genetics, 2001, 29, 66-69.	21.4	523
9	Narcolepsy is strongly associated with the T-cell receptor alpha locus. Nature Genetics, 2009, 41, 708-711.	21.4	445
10	Common Variants at 10 Genomic Loci Influence Hemoglobin A1C Levels via Glycemic and Nonglycemic Pathways. Diabetes, 2010, 59, 3229-3239.	0.6	387
11	Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nature Genetics, 2013, 45, 670-675.	21.4	339
12	Class II HLA interactions modulate genetic risk for multiple sclerosis. Nature Genetics, 2015, 47, 1107-1113.	21.4	312
13	Restless legs syndrome associated with major diseases. Neurology, 2016, 86, 1336-1343.	1.1	276
14	Diagnostic Standards for Dopaminergic Augmentation of Restless Legs Syndrome: Report from a World Association of Sleep Medicine â€“ International Restless Legs Syndrome Study Group Consensus Conference at the Max Planck Institute. Sleep Medicine, 2007, 8, 520-530.	1.6	264
15	PTPRD (protein tyrosine phosphatase receptor type delta) is associated with restless legs syndrome. Nature Genetics, 2008, 40, 946-948.	21.4	252
16	Genome-wide Association Analysis of Psoriatic Arthritis and Cutaneous Psoriasis Reveals Differences in Their Genetic Architecture. American Journal of Human Genetics, 2015, 97, 816-836.	6.2	245
17	Guidelines for the first-line treatment of restless legs syndrome/Willisâ€“Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation. Sleep Medicine, 2016, 21, 1-11.	1.6	242
18	Complex segregation analysis of restless legs syndrome provides evidence for an autosomal dominant mode of inheritance in early age at onset families. Annals of Neurology, 2002, 52, 297-302.	5.3	229

#	Article	IF	Citations
19	Mutations in DNMT1 cause autosomal dominant cerebellar ataxia, deafness and narcolepsy. Human Molecular Genetics, 2012, 21, 2205-2210.	2.9	225
20	Absence of an Orphan Mitochondrial Protein, C19orf12, Causes a Distinct Clinical Subtype of Neurodegeneration with Brain Iron Accumulation. American Journal of Human Genetics, 2011, 89, 543-550.	6.2	224
21	Epidemiology of restless legs syndrome: The current status. Sleep Medicine Reviews, 2006, 10, 153-167.	8.5	219
22	Common variants in P2RY11 are associated with narcolepsy. Nature Genetics, 2011, 43, 66-71.	21.4	215
23	ImmunoChip Study Implicates Antigen Presentation to T Cells in Narcolepsy. PLoS Genetics, 2013, 9, e1003270.	3.5	206
24	Longâ€Term followâ€up on restless legs syndrome patients treated with opioids. Movement Disorders, 2001, 16, 1105-1109.	3.9	195
25	Novel loci affecting iron homeostasis and their effects in individuals at risk for hemochromatosis. Nature Communications, 2014, 5, 4926.	12.8	192
26	Prolonged release oxycodoneâ€“naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension. Lancet Neurology, The, 2013, 12, 1141-1150.	10.2	188
27	Longâ€term course of restless legs syndrome in dialysis patients after kidney transplantation. Movement Disorders, 2002, 17, 1072-1076.	3.9	183
28	High-density genotyping study identifies four new susceptibility loci for atopic dermatitis. Nature Genetics, 2013, 45, 808-812.	21.4	167
29	Genome-Wide Association Study Identifies Novel Restless Legs Syndrome Susceptibility Loci on 2p14 and 16q12.1. PLoS Genetics, 2011, 7, e1002171.	3.5	163
30	Mitochondrial membrane protein associated neurodegenration: A novel variant of neurodegeneration with brain iron accumulation. Movement Disorders, 2013, 28, 224-227.	3.9	162
31	Association Between Variants of PRDM1 and NDP52 and Crohn's Disease, Based on Exome Sequencing and Functional Studies. Gastroenterology, 2013, 145, 339-347.	1.3	149
32	Heritability of Sleep Electroencephalogram. Biological Psychiatry, 2008, 64, 344-348.	1.3	146
33	Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups. Annals of the Rheumatic Diseases, 2016, 75, 1558-1566.	0.9	127
34	Opioid and dopamine antagonist drug challenges in untreated restless legs syndrome patients. Sleep Medicine, 2001, 2, 57-61.	1.6	104
35	Variants in the neuronal nitric oxide synthase (nNOS, NOS1) gene are associated with restless legs syndrome. Movement Disorders, 2008, 23, 350-358.	3.9	103
36	Restless Legs Syndrome-associated intronic common variant in Meis1 alters enhancer function in the developing telencephalon. Genome Research, 2014, 24, 592-603.	5.5	102

#	Article	IF	Citations
37	Periodic Leg Movements during Sleep Are Associated with Polymorphisms in BTBD9, TOX3/BC034767, MEIS1, MAP2K5/SKOR1, and PTPRD. Sleep, 2014, 37, 1535-1542.	1.1	102
38	Restless legs syndrome. Current Opinion in Pulmonary Medicine, 2013, 19, 594-600.	2.6	97
39	Identification of Immune-Relevant Factors Conferring Sarcoidosis Genetic Risk. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 727-736.	5.6	94
40	Clinical exome sequencing in earlyâ€onset generalized dystonia and largeâ€scale resequencing followâ€up. Movement Disorders, 2017, 32, 549-559.	3.9	94
41	Recent advances in the diagnosis, genetics and treatment of restless legs syndrome. Journal of Neurology, 2009, 256, 539-553.	3.6	91
42	Action myoclonus-renal failure syndrome: characterization of a unique cerebro-renal disorder. Brain, 2004, 127, 2173-2182.	7.6	89
43	Augmentation as a treatment complication of restless legs syndrome: Concept and management. Movement Disorders, 2007, 22, S476-S484.	3.9	81
44	Evidence for further genetic locus heterogeneity and confirmation of RLSâ€1 in restless legs syndrome. Movement Disorders, 2006, 21, 28-33.	3.9	79
45	Recessive Mutations in the Î±3 (VI) Collagen Gene COL6A3 Cause Early-Onset Isolated Dystonia. American Journal of Human Genetics, 2015, 96, 883-893.	6.2	79
46	Restless legs syndromeâ€"current therapies and management of augmentation. Nature Reviews Neurology, 2015, 11, 434-445.	10.1	74
47	Genetics of restless legs syndrome (RLS): State-of-the-art and future directions. Movement Disorders, 2007, 22, S449-S458.	3.9	73
48	Shortâ€term attention and verbal fluency is decreased in restless legs syndrome patients. Movement Disorders, 2010, 25, 2641-2648.	3.9	65
49	Association of CLEC16A with human common variable immunodeficiency disorder and role in murine B cells. Nature Communications, 2015, 6, 6804.	12.8	63
50	Novel association to the proprotein convertase PCSK7 gene locus revealed by analysing soluble transferrin receptor (sTfR) levels. Human Molecular Genetics, 2011, 20, 1042-1047.	2.9	62
51	Sleep and periodic limb movements in corticobasal degeneration. Sleep Medicine, 2002, 3, 33-36.	1.6	61
52	Suggestive evidence for linkage for restless legs syndrome on chromosome 19p13. Neurogenetics, 2008, 9, 75-82.	1.4	61
53	MEIS1 and BTBD9: genetic association with restless leg syndrome in end stage renal disease. Journal of Medical Genetics, 2011, 48, 462-466.	3.2	59
54	HLA DQB1*06:02 Negative Narcolepsy with Hypocretin/Orexin Deficiency. Sleep, 2014, 37, 1601-1608.	1.1	59

#	Article	IF	Citations
55	When Parkinsonâ€™s disease patients go to sleep: specific sleep disturbances related to Parkinsonâ€™s disease. Journal of Neurology, 2011, 258, 328-335.	3.6	56
56	Genetics of restless legs syndrome. Current Neurology and Neuroscience Reports, 2008, 8, 211-216.	4.2	55
57	Targeted Resequencing and Systematic InÂVivo Functional Testing Identifies Rare Variants in MEIS1 as Significant Contributors to Restless Legs Syndrome. American Journal of Human Genetics, 2014, 95, 85-95.	6.2	52
58	Rare variants in Î²-Amyloid precursor protein (APP) and Parkinsonâ€™s disease. European Journal of Human Genetics, 2015, 23, 1328-1333.	2.8	50
59	Niemann-Pick C Disease Gene Mutations and Age-Related Neurodegenerative Disorders. PLoS ONE, 2013, 8, e82879.	2.5	50
60	Narcolepsy is a common phenotype in HSAN IE and ADCA-DN. Brain, 2014, 137, 1643-1655.	7.6	49
61	Rare sequence variants in ANO3 and GNAL in a primary torsion dystonia series and controls. Movement Disorders, 2014, 29, 143-147.	3.9	49
62	Parkinsonâ€™s disease risk score: moving to a premotor diagnosis. Journal of Neurology, 2011, 258, 311-315.	3.6	46
63	Paroxetine treatment improves motor symptoms in patients with multiple system atrophy. Parkinsonism and Related Disorders, 2006, 12, 432-437.	2.2	44
64	The role of <scp>SCARB2</scp> as susceptibility factor in <scp>P</scp>arkinson's disease. Movement Disorders, 2013, 28, 538-540.	3.9	41
65	Treatment of restless leg syndrome with pergolide-an open clinical trial. Movement Disorders, 1998, 13, 566-569.	3.9	40
66	Genetics of restless legs syndrome. Sleep Medicine Reviews, 2006, 10, 179-183.	8.5	39
67	Genetic variants in the immunoglobulin heavy chain locus are associated with the IgG index in multiple sclerosis. Annals of Neurology, 2013, 73, 86-94.	5.3	38
68	DYT16 revisited: Exome sequencing identifiesPRKRAmutations in a European dystonia family. Movement Disorders, 2014, 29, 1504-1510.	3.9	38
69	Rare variants in LRRK1 and Parkinson's disease. Neurogenetics, 2014, 15, 49-57.	1.4	33
70	Dilution of candidates: the case of iron-related genes in restless legs syndrome. European Journal of Human Genetics, 2013, 21, 410-414.	2.8	32
71	Family-based association study of the restless legs syndrome loci 2 and 3 in a European population. Movement Disorders, 2007, 22, 207-212.	3.9	31
72	Alterations in Lipid and Inositol Metabolisms in Two Dopaminergic Disorders. PLoS ONE, 2016, 11, e0147129.	2.5	31

#	Article	IF	Citations
73	Variants in eukaryotic translation initiation factor 4G1 in sporadic Parkinsonâ€™s disease. Neurogenetics, 2012, 13, 281-285.	1.4	30
74	Variation within the Huntington's Disease Gene Influences Normal Brain Structure. PLoS ONE, 2012, 7, e29809.	2.5	30
75	Pergolide restores sleep maintenance but impairs sleep EEG synchronization in patients with restless legs syndrome. Sleep Medicine, 2002, 3, 49-54.	1.6	29
76	Assessment of spontaneously occurring periodic limb movements in sleep in the rat. Journal of the Neurological Sciences, 2002, 198, 71-77.	0.6	28
77	<scp>PSEA</scp>: Phenotype Set Enrichment Analysisâ€”A New Method for Analysis of Multiple Phenotypes. Genetic Epidemiology, 2012, 36, 244-252.	1.3	24
78	Novel SCARB2 mutation in action myoclonus-renal failure syndrome and evaluation of SCARB2mutations in isolated AMRF features. BMC Neurology, 2011, 11, 134.	1.8	22
79	Aetiology and Treatment of Restless Legs Syndrome. CNS Drugs, 1999, 12, 9-20.	5.9	21
80	Current treatment options for restless legs syndrome. Expert Opinion on Pharmacotherapy, 2003, 4, 1727-1738.	1.8	18
81	Olanzapine-induced Oculogyric Crisis. Journal of Clinical Psychopharmacology, 2006, 26, 431.	1.4	18
82	Excess of rare coding variants in PLD3 in late- but not early-onset Alzheimerâ€™s disease. Human Genome Variation, 2015, 2, 14028.	0.7	18
83	High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias. Parkinsonism and Related Disorders, 2005, 11, 393-398.	2.2	17
84	Myoclonusâ€dystonia in 18p deletion syndrome. Movement Disorders, 2011, 26, 560-561.	3.9	17
85	Indications for Performing Polysomnography in the Diagnosis and Treatment of Restless Legs Syndrome. Indikationen zur Polysomnographie in der Diagnose und Therapie des Restless Legs Syndroms. Somnologie, 2001, 5, 159-162.	1.5	16
86	Rare Variants in PLXNA4 and Parkinsonâ€™s Disease. PLoS ONE, 2013, 8, e79145.	2.5	16
87	Clinical trials in restless legs syndromeâ€”Recommendations of the European RLS Study Group (EURLSSG). Movement Disorders, 2007, 22 Suppl 18, S495-504.	3.9	15
88	Genetics of restless legs syndrome. Neurology, 2008, 70, 664-665.	1.1	13
89	The clinical phenotype of earlyâ€onset isolated dystonia caused by recessive COL6A3 mutations (DYT27). Movement Disorders, 2016, 31, 747-750.	3.9	13
90	Animal studies in restless legs syndrome. Movement Disorders, 2007, 22, S459-S465.	3.9	12

#	Article	IF	Citations
91	Genetics of Restless Legs Syndrome: Mendelian, Complex, and Everything in Between. Sleep Medicine Clinics, 2011, 6, 203-215.	2.6	12
92	When restless legs syndrome turns malignant. Sleep Medicine, 2013, 14, 575-577.	1.6	10
93	Genetics of sleep disorders. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2011, 99, 681-693.	1.8	7
94	Large-scale TUBB4A mutational screening in isolated dystonia and controls. Parkinsonism and Related Disorders, 2015, 21, 1278-1281.	2.2	7
95	Mutational screening of THAP1 in a German population with primary dystonia. Parkinsonism and Related Disorders, 2012, 18, 104-106.	2.2	6
96	Polysomnographic and neurometabolic features may mark preclinical autosomal dominant cerebellar ataxia, deafness, and narcolepsy due to a mutation in the DNA (cytosine-5-)-methyltransferase gene, DNMT1. Sleep Medicine, 2014, 15, 582-585.	1.6	6
97	The Restless Legs Syndrome - A Genetic View of the Disease. Das Restless Legs Syndrom aus genetischer Sicht. Somnologie, 2002, 6, 3-6.	1.5	5
98	Iron in Restless Legs Syndrome. Movement Disorders Clinical Practice, 2014, 1, 161-172.	1.5	4
99	TOR1A, THAP1, and GNAL mutational screening in Austrian patients with primary isolated dystonia. Movement Disorders, 2015, 30, 1853-1854.	3.9	4
100	Systematic TOR1A non-c.907_909delGAG variant analysis in isolated dystonia and controls. Parkinsonism and Related Disorders, 2016, 31, 119-123.	2.2	4
101	SOX5-Null Heterozygous Mutation in a Family with Adult-Onset Hyperkinesia and Behavioral Abnormalities. Case Reports in Genetics, 2017, 2017, 1-6.	0.2	4
102	Blood cis-eQTL Analysis Fails to Identify Novel Association Signals among Sub-Threshold Candidates from Genome-Wide Association Studies in Restless Legs Syndrome. PLoS ONE, 2014, 9, e98092.	2.5	2
103	Erratum to â€œDiagnostic standards for dopaminergic augmentation of restless legs syndrome: Report from a World Association of Sleep Medicine â€“ International Restless Legs Syndrome Study Group consensus conference at the Max Planck Instituteâ€•[Sleep Med. 8 (2007) 520â€“530]. Sleep Medicine, 2007, 8, 788.	1.6	1
104	Network-based SNP meta-analysis identifies joint and disjoint genetic features across common human diseases. BMC Genomics, 2012, 13, 490.	2.8	1
105	Reply to letter: Novel compound heterozygous mutations in PRKRA cause pure dystonia. Movement Disorders, 2015, 30, 878-879.	3.9	1
106	â€œMalignant restless legs syndromeâ€â€”A curse or a blessing?. Sleep Medicine, 2014, 15, 155-156.	1.6	0
107	Clinical Phenotype and Genetics of Restless Legs Syndrome. , 2015, , 1145-1162.		0
108	Das Restless-legs-Syndrom (RLS). , 2003, , 131-142.		0

#	Article	IF	Citations
109	Genetics of Restless Legs Syndrome (RLS). , 2015, , 331-351.		0